Correction: Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma. by Xinqi Wu, Melina E Marmarelis, F Stephen Hodi

Get full text

Gaps in the management of adrenal insufficiency in melanoma survivors: a retrospective cohort studyResearch in context by Wei Lin, Wei Wang, F. Stephen Hodi, Le Min

Get full text

Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma by Trevor E. Angell, Le Min, Tad J. Wieczorek, F. Stephen Hodi

Get full text

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome by F Stephen Hodi, Mizuki Nishino, Nikhil H Ramaiya, Anita Giobbie-Hurder

Get full text

Cancer immunotherapy trials: leading a paradigm shift in drug development by Leisha A Emens, F. Stephen Hodi, Lisa H. Butterfield, Howard L. Kaufman, Francesco M. Marincola

Get full text

Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor... by Tamara A. Sussman, Mariano Severgnini, Mariano Severgnini, Anita Giobbie-Hurder, Anita Giobbie-Hurder, Philip Friedlander, Scott J. Swanson, Michael Jaklitsch, Thomas Clancy, Laura A. Goguen, David Lautz, Richard Swanson, Heather Daley, Jerome Ritz, Jerome Ritz, Glenn Dranoff, F. Stephen Hodi, F. Stephen Hodi

Get full text

Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients by F. Stephen Hodi, Jonathan Schoenfeld, Mariano Severgnini, Vishwajith Sridharan, Danielle N. Margalit, Stephanie A. Lynch, Robert I. Haddad, Roy B. Tishler

Get full text

Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients by F. Stephen Hodi, Pasi A. Janne, Mark M. Awad, Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers, Anika E. Adeni, Hiroto Hatabu

Get full text

C reactive protein impairs adaptive immunity in immune cells of patients with melanoma by Jeffrey Weber, Michelle Krogsgaard, Tatsuya Yoshida, Junya Ichikawa, Iulia Giuroiu, Andressa S Laino, Yuhan Hao, Melinda Vassallo, David M Woods, F Stephen Hodi

Get full text

A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade by Peter G. Miller, Adam S. Sperling, Christopher J. Gibson, Olga Pozdnyakova, Waihay J. Wong, Michael P. Manos, Elizabeth I. Buchbinder, F. Stephen Hodi, Benjamin L. Ebert, Matthew S. Davids

Get full text

Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients by Yves Boucher, Ashwin S. Kumar, Jessica M. Posada, Evisa Gjini, Kathleen Pfaff, Mikel Lipschitz, Ana Lako, Dan G. Duda, Scott J. Rodig, F. Stephen Hodi, Rakesh K. Jain

Get full text

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy by Matthias Pauschinger, F. Stephen Hodi, Patrick A. Ott, Thomas F. Gajewski, Hussein Tawbi, Jason J. Luke, Lucie Heinzerling, Aliya N. Husain, Azadeh Tajmir-Riahi, Evan J. Lipson

Get full text

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma by Bin Zhang, F. Stephen Hodi, Asim Amin, David H. Lawson, April K.S. Salama, Henry B. Koon, Troy Guthrie, Sajeve S. Thomas, Steven J. O’Day, Montaser F. Shaheen, Stephen Francis

Get full text

A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma by Sebastian Bauer, James Larkin, F. Stephen Hodi, Frank Stephen, Frank Stephen, Ellen H. W. Kapiteijn, Gary K. Schwartz, Emilano Calvo, Padmaja Yerramilli-Rao, Sophie Piperno-Neumann, Richard D. Carvajal

Get full text

Soluble PD-L1 as an early marker of progressive disease on nivolumab by David F McDermott, Gordon J Freeman, Toni K Choueiri, Petra Ross-MacDonald, F Stephen Hodi, Megan Wind-Rotolo, Long Yuan, Kathleen M Mahoney, Linan Song, Eliseo Veras

Get full text

Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab by David Liu, F Stephen Hodi, Rizwan Haq, Anita Giobbie-Hurder, Ann W Silk, Patrick A Ott, Tamara A Sussman, Elizabeth I Buchbinder, Anna K Maloney, Nikita Katukota, Miklos C Fogarasi, Megan Insco

Get full text

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors by Howard Streicher, Elad Sharon, Mariano Severgnini, Michael Manos, Anita Giobbie-Hurder, F Stephen Hodi, Andrew S Brohl, Philippe L Bedard, Kevin Tyan, Scott Rodig, Osama E Rahma, Daniel J Renouf, Emma Hathaway, Rachel Cunningham

Get full text

Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service by Michael Manos, Patrick Ott, Osama Rahma, F Stephen Hodi, Shilpa Grover, Peter Bowling, Jian Ni, Nicole R LeBoeuf, Osama Abu-Shawer, Prabhsimranjot Singh, Eric Yenulevich, Amanda Brito, Raja-Elie E Abdulnour, Joseph Jacobson

Get full text

578 Anti-PD-1 therapy alters the generation and durability of de novo responses to vaccination in humans by Michael Manos, Arlene Sharpe, F Stephen Hodi, Joanna Baginska, Elizabeth I Buchbinder, Marta Holovatska, Kelly P Burke, Taras M Chicz, Julia Huezo, Duck Kyun Yoo, Fnu Keerti, Caihong Bi, Ryan McNamara, Duane Wesemann

Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicent... by Toshihiko Doi, David Tai, Dong-Wan Kim, F Stephen Hodi, Sofie Wilgenhof, Catherine Sabatos-Peyton, Giuseppe Curigliano, Chia-Chi Lin, Armando Santoro, Alexandros Xyrafas, Nicolas Mach, Sebastian Szpakowski, Shripad Chitnis, Sabine Gutzwiller, Alessandro Pastore

Get full text